CJC-1295 / Ipamorelin Blend

GHRH + GHRP Dual Stack | Synergistic Growth Hormone Research

This blend combines CJC-1295 (without DAC, also known as Mod GRF 1-29) at 5mg with Ipamorelin at 5mg — two peptides from distinct mechanistic classes that research literature suggests may act synergistically on the pituitary-hypothalamic axis.

CJC-1295 (no DAC) is a GHRH analogue that stimulates the pituitary to produce growth hormone through the GHRH receptor. Ipamorelin is a selective growth hormone releasing peptide (GHRP) and ghrelin receptor agonist. When studied together, the two compounds engage separate but complementary receptor pathways, which research has associated with amplified GH pulse amplitude compared to either compound alone.

Ipamorelin is notable in the GHRP class for its high selectivity — studies indicate it does not significantly elevate cortisol or ACTH, distinguishing it from earlier generation GHRPs such as GHRP-6. This selectivity profile makes the CJC-1295 / Ipamorelin combination of interest to researchers examining GH secretagogue specificity and pituitary signalling.

Supplied as lyophilised powder. Each vial contains CJC-1295 (no DAC) 5mg + Ipamorelin 5mg. Purity ≥99% by HPLC. Third-party Certificate of Analysis available — tested by Janoshik Analytical (Prague) and issued in Longev Peptides' name.

For research use only. Not for human consumption.